All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site

Theo de WitteChair

Professor Theo de Witte, chair of the MDS Hub, ran the Hematology Department at Radboud University Medical Center, Nijmegen, NL, from 1990 to 2009, following which he continued his clinical and scientific research in the Departments of Tumor Immunology and Hematology. 

Professor de Witte has been, and still is, active on many national and international scientific boards, for example, he is a board member of the international MDS Foundation and a member of the steering committee for the European LeukemiaNet (ELN). He was also the chief investigator and project leader of the EUMDS Registry and coordinator of the MDS-RIGHT project. Currently, he is a senior consultant of the EUMDS-Registry and the ELN MDS Workpackage .  

Professor de Witte's main scientific interests are the biology and treatment of myelodysplastic syndromes/acute myeloid leukemia and cellular immunotherapy of hematologic malignancies.